Try our Advanced Search for more refined results
Life Sciences - December, 2006
80 articles
- Antitrust Litigation Yielded $3.4B In 2006: Survey
- Antitrust Litigation Surged In 2006: Survey
- Authorized Generics: An Issue To Watch In 2007
- IP Litigation Yielded $3.4B In 2006: Survey
- Democrats To Push For Medicare Changes In 2007
- Congress Eyes Generic Biotech Drugs
- Cases To Watch In 2007
- Doctor Files Patent Suit Against Tyco Healthcare
- Bristol-Myers To Pay $499M To Settle Pricing Charges
- AstraZeneca's Legal Troubles Continue To Mount
- Judge Rejects Ivax Challenges To Depomed Patents
- "Logic Bomb" Lands Ex-Employee In Court
- Par Pharma Hit With Patent Suit Over Rythmol ANDA
- Companies Tangle Over Laser Technology
- Incoming N.Y. Attorney General Names Dream Team
- Enzo Challenges Bioequivalence Standard
- Erectile-Dysfunction Ruling Allowed To Stand
- Deaths Prompt Warnings On Rituxan
- Australian Court Bars Ranbaxy's Generic Lipitor
- Europe Strips AstraZeneca Of Key Nexium Patent
- Biovail Sues FDA Over Generic Wellbutrin
- Pharmacy Board Insists Generics Are Undersold
- Do Pay-For-Placement Search Engines Engage In Trademark "Use"?
- Drugmakers Rail Against Compulsory Licensing
- Ortho-McNeil Sues Barr Over Topamax Generic
- Drug Co. Claims Licensee Breached ProQuin Deal
- Eli Lilly Disputes New York Times Report
- Epix Plans To Appeal FDA Drug Decision
- Catheter Maker Settles Antitrust Suit For $49M
- FDA Delays Decision On Roche Anemia Drug
- Europe To Review Validity Of Key Nexium Patent
- License Agreement Turns Biotech Partners Into Rivals
- Novartis Sues To Protect Hypertension Drug
- Injunction Against Pfizer's Exubera Tossed Out
- FDA Lacks Timeliness In Reviewing Drug Ads: Report
- Merck: Vioxx Litigation Strategy Is Working
- Savient Secures Last-Minute Generic Oxandrin Ban
- FTC Allows J&J To Buy Pfizer Unit If It Sells 4 Brands
- Teaching, Suggestion, Motivation, Common Sense, And Gobbledygook In The Supreme Court
- Court Tosses Enzo Biochem Class Action
- Jury Mulls Arguments In Latest Vioxx Trial
- Accusations Fly Over Contraceptive Patch
- E.U. Approves J&J Buyout Of Pfizer Unit
- Attorney Mistake Dooms Angiomax Patent Extension
- Drugstores Sue AstraZeneca Over Nexium
- FTC Greenlights Barr's $2.5B Takeover Of Pliva
- McKesson Sues Over Healthcare Software Patent
- Judge Lifts Generic Oxandrin Ban
- NIH Scientist Pleads Guilty
- Court Blocks Teva's Bid To Sell Generic Lipitor
- Federal Circuit Upholds Ban On Generic Plavix
- Securities Fraud Suit Follows Pfizer's Drug Collapse
- Skeptical Congress Approves FDA Chief
- Johnson & Johnson Faces Stent Suit
- Pfizer, Mylan Await Decision In Norvasc Patent Case
- Genentech, Tercica Prevail In Suit Against Insmed
- AmeriGroup Braces For Massive Damages Award
- Fish & Richardson Reels In Another Attorney
- Patent Attorneys Leave Sonnenschein To Found Firm
- Avian Flu Infects Veterinary Medical Antitrust Suit
- Law Firm Profile: Pitney Hardin LLP
- Savient Wins Generic Restraining Order For Oxandrin
- Attorney General Insists Wal-Mart, Target Have It Wrong
- Medtronic Reveals $75M Settlement Over Patents
- Federal Injunction Stays Portion Of Drug Distribution Law
- Alzheimer's Scientist In Hot Water Over Pfizer Work
- Merck Sues Apotex Over Eye Treatments
- Paxil Caused Birth Defects, Lawsuit Claims
- Supreme Court Skeptical About Federal Circuit's Obviousness Test
- Law Firm Profile: Holland & Knight LLP
- Sydney Snapshot: Corrs Chambers Westgarth
- Thailand Breaks Merck's Patent For AIDS Drug
- Appeals Court Affirms Dismissal Of Drug Importation Suit
- Savient Sues More Generic Cos. Over Weight-Gain Drug
- Sydney Snapshot: Deacons
- Sydney Snapshot: Blake Dawson
- NeoPharm Will Not Face SEC Charges
- Sanofi-Aventis Continues To Face Trouble Over Ketek
- Sydney Snapshot: Minter Ellison
- Magistrate Recommends Stay In Pharmaceutical Case